Molbio Diagnostics raises ₹281 cr from anchor investors ahead of IPO
The IPO, with a price band of ₹768-807 per share, will open for public subscription on August 10 and conclude on August 12
Diagnostics firm Molbio Diagnostics secured ₹281.5 crore from prominent investors prior to its IPO listing. The company sold 34.88 lakh shares to 33 anchor investors at ₹807 each, which was the top price in the range. Major anchor investors included Goldman Sachs, BlackRock Global Funds, Motilal Oswal Private Equity, and several mutual funds.
The IPO, priced between ₹768 and ₹807 per share, will be open for public subscription on August 10 and close on August 12. The initial public offering is anticipated to generate ₹904 crore to ₹940 crore at the lower and higher ends of the price band. Molbio Diagnostics will use the fresh issue proceeds for capital expenditure on infrastructure development and equipment purchase, with the remaining funds allocated for general corporate purposes.
The company aims to achieve a post-IPO market valuation of approximately ₹9,300 crore at the higher end of the price range. Established in 2000, Molbio Diagnostics develops lab-on-a-chip technology for point-of-care testing of 30 diseases. Their battery-operated "Truenat" platform enables rapid diagnosis within an hour, operating from six manufacturing facilities in India.
As of March 2026, the company's installed capacity was 5,400 devices per annum and 3.9 crore test kits annually. The shares are set to be listed on the BSE and NSE on August 17.
Written by urgent.news from Hindu BusinessLine's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
Also reported by 1 other outlet
- Dhoot Transmission collects ₹918 cr from anchor investors; IPO to open on Aug 10 thehindubusinessline.com
